Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fluoxetine and Raynaud's phenomenon: friend or foe?

Literature DB >> 28580711

Fluoxetine and Raynaud's phenomenon: friend or foe?

Charles Khouri^1,2, Thomas Gailland¹, Marion Lepelley¹, Matthieu Roustit^2,3, Jean-Luc Cracowski^2,3.

Abstract

Entities: Chemical

Keywords: Raynaud's phenomenon; fluoxetine; systemic sclerosis

Mesh：

Substances：

Year: 2017 PMID： 28580711 PMCID： PMC5595930 DOI： 10.1111/bcp.13314

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

15 in total

1. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Authors: B Coleiro; S E Marshall; C P Denton; K Howell; A Blann; K I Welsh; C M Black
Journal: Rheumatology (Oxford) Date: 2001-09 Impact factor: 7.580

2. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors.

Authors: Stephen Ph Alexander; Anthony P Davenport; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739

Review 3. The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis.

Authors: J D Pauling; V B O'Donnell; N J Mchugh
Journal: Platelets Date: 2012-09-11 Impact factor: 3.862

4. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739

5. Serotonin reuptake inhibitors in Raynaud's phenomenon.

Authors: I A Jaffe
Journal: Lancet Date: 1995-05-27 Impact factor: 79.321

6. Fluoxetine dilates isolated small cerebral arteries of rats and attenuates constrictions to serotonin, norepinephrine, and a voltage-dependent Ca(2+) channel opener.

Authors: Z Ungvari; P Pacher; V Kecskeméti; A Koller
Journal: Stroke Date: 1999-09 Impact factor: 7.914

7. Update of EULAR recommendations for the treatment of systemic sclerosis.

Authors: Otylia Kowal-Bielecka; Jaap Fransen; Jerome Avouac; Mike Becker; Agnieszka Kulak; Yannick Allanore; Oliver Distler; Philip Clements; Maurizio Cutolo; Laszlo Czirjak; Nemanja Damjanov; Francesco Del Galdo; Christopher P Denton; Jörg H W Distler; Ivan Foeldvari; Kim Figelstone; Marc Frerix; Daniel E Furst; Serena Guiducci; Nicolas Hunzelmann; Dinesh Khanna; Marco Matucci-Cerinic; Ariane L Herrick; Frank van den Hoogen; Jacob M van Laar; Gabriela Riemekasten; Richard Silver; Vanessa Smith; Alberto Sulli; Ingo Tarner; Alan Tyndall; Joep Welling; Frederic Wigley; Gabriele Valentini; Ulrich A Walker; Francesco Zulian; Ulf Müller-Ladner
Journal: Ann Rheum Dis Date: 2016-11-09 Impact factor: 19.103

8. Chronic fluoxetine treatment increases NO bioavailability and calcium-sensitive potassium channels activation in rat mesenteric resistance arteries.

Authors: Camila A Pereira; Nathanne S Ferreira; Fabiola L Mestriner; José Antunes-Rodrigues; Paulo R B Evora; Leonardo B M Resstel; Fernando S Carneiro; Rita C Tostes
Journal: Eur J Pharmacol Date: 2015-09-08 Impact factor: 4.432

9. Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling.

Authors: Keren Ofek; Karl Schoknecht; Naomi Melamed-Book; Uwe Heinemann; Alon Friedman; Hermona Soreq
Journal: J Cell Mol Med Date: 2012-11 Impact factor: 5.310

10. The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels.

Authors: Stephen Ph Alexander; William A Catterall; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739

3 in total